Pre-qualification Program: Priority Medicines Interchangeability of Multi Source Drug Products Interchangeability of Multisource Drug Products Containing Highly Variable Drugs SALOMON STAVCHANSKY, PH.D. ALCON CENTENNIAL PROFESSOR OF PHARMACEUTICS THE UNIVERSITY OF TEXAS AT AUSTIN COLLEGE OF PHARMACY AUSTIN, TEXAS 78712 stavchansky@mail.utexas.edu Kiev, Ukraine, June 25-27, 2007 Outline • Background – What is a highly variable drug? – Present bioequivalence BE study approach – Disadvantages of present approach • Bioequivalence Example of Highly Variable Drugs • Reference – scaled average BE approach – Widening the bioequivalence limits – scaling • Simulation Studies • Summary and Conclusions Questions • Why? – Have you ever had or heard of a therapeutic failure • Where do we want to be? – No therapeutic failures and no adverse events • What assumptions are we willing to make? – Multisource products are interchangeable with brand products • How sure do you want to be? – How to protect the consumer and the industry? DRUG DEVELOPMENT PROCESS AND REGULATIONS CONTROLLED CLINICAL TRIALS EFFICACY SAFETY THERAPEUTIC INDEX SAMENESS CLINICAL PHARMACOLOGY P'KINETICS BIOPHARMACEUTICS VARIABILITY IN DRUG RESPONSE PRODUCT QUALITY P'DYNAMICS DISSOLUTION BA, BE DOSE ADJUSTMENT FOR RISK GROUPS DOSE RANGE FOR TARGET POPULATION DOSE RANGE IN LABEL DOSE B aber, N .S., B r.J.C lin.Pharmacol.,42,545,1996 INDIVIDUALIZATION Highly Variable Drug Characteristics • Drugs with high within subject variability (CVwr) in bioavailability parameters AUC and/or Cmax ≥ 30% • Non narrow therapeutic index drugs • Represent about 10% of the drugs studied in vivo and reviewed by the OGD-FDA HVD Drug Products • Highly Variable Drug Products in which the drug is not highly variable, but the product is of poor pharmaceutical quality – High within-formulation variability Variability Due to Drug Substance and/or Drug Product • Drug Substance – Variable absorption rate, extent – Low extent of absorption – Extensive pre-systemic metabolism • Drug product – Formulation • Inactive ingredient effects • Manufacturing effects – Effects of Bioequivalence Study Conduct • Bioanalytical Assay Sensitivity • Suboptimal PK Sampling Summary of the issues • High Probability that the BE parameters will vary when the same subject receives a highly variable drug on different occasions • Because of high variability the risk is to reject a product that in reality is bioequivalent -- Industry Risk ! FDA Study to Characterize Highly Variable Drugs in BE Studies: methods • Collected data from 1127 acceptable BE studies, submitted – In 524 ANDAs – From 2003-2005 (3 years) • Most sponsors used 2-way crossover studies – Used ANOVA Root Mean Square Error to estimate within-subject variance • Drug was classified as highly variable if RMSE ≥ 0.3 or 30% Source: Barbara M. Davit AAPS/FDA Workshop 5/22/2077, Rockville, MD FDA Study to Characterize Highly Variable Drugs in BE Studies: results • BE studies of HVD enrolled more study subjects than studies of drugs with low variability – Average N in studies of HVD = 47 – Average N in studies of drugs with lower variability = 33 • Range 18 – 73 subjects Source: Barbara M. Davit AAPS/FDA Workshop 5/22/2077, Rockville, MD FDA Study to Characterize Highly Variable Drugs in BE Studies: results • 10% of studies evaluated were HVD; of these: – 52% of studies were consistently HVD – 16% were borderline • RMSE was slightly above or below 0.3 • Average across all studies – For the remaining 32%, high variability occurred sporadically • Not HVD in most BE studies Reasons for Inconsistent Variability in BE Studies • • • • • • Differences in formulations Bioanalytical assay sensitivity Demographic characteristics of subjects Subjects with irregular plasma concentrations Number of study subjects Whether subjects were fasted or fed Source: Barbara M. Davit AAPS/FDA Workshop 5/22/2077, Rockville, MD Present FDA Approach for BE of HVD • ANDAs for HVD use the same study design for drugs with lower variability • Two way crossover design • Replicate study design • Firms are encouraged to use sequential designs Present FDA Approach for BE of HVD • HVD must meet same acceptance criteria as drugs with lower variability • 90% CI of AUC and Cmax test/reference (T/R ratios) must fall within: 0.8-1.25 (80-125%) • Statistical adjustment necessary if a sequential study design is used Is present FDA’s approach suitable for HVD? Approach Disadvantage Enrolled adequate # of Study may require larger N subjects (N) to show BE in 2 If study underpowered way crossover study must do new study Replicate design ( 4period) study High dropout rate; may need to enroll larger N EXPENSIVE Group sequential design Must specify in protocol a priori Statistical Adjustment Source: Barbara M. Davit AAPS/FDA Workshop 5/22/2077, Rockville, MD Background for NEW approach ACPS Meeting, April 14, 2004: Discussion on Highly Variable Drugs • Different approaches were considered, e.g., expansion of bioequivalence limits, and scaled average bioequivalence • Committee favored scaled average bioequivalence over other approaches • FDA working group was created; a research project to evaluate scaling was initiated ACPS = Advisory Committee for Pharmaceutical Science The Width of the 90% Confidence Interval • The width depends on: – Within subject variability WSV – The number of subjects in the study • The wider the 90% CI, the more likely it is to fall outside the limits of 80-125% • Highly variable drugs are a problem 90%CIs & BE Limits • Green – Low WSV (~15%) – Narrow 90%CI – Passes • Red – – – – High WSV (~35%) Wide 90%CI Lower bound <80% Fails 125% 100% 80% • GMR & the # subjects same in both cases Chlorpromazine: ANOVA-CV% ln Cmax ln AUClast aBioequivalence Study 1a Study 2b Study 3c 42.3 34.8 39.9 36.6 37.2 33.0 study, n=37 (3-period study) study n=11 (solution, 3-period study) cPharmacokinetic study, n=9, CPZ with & without quinidine (2-period study) bPharmacokinetic Cmax Ref-1 AUClast Ref-1 Ref-2 Ref-2 6 16 20 6 7 13 6 13 7 16 13 13 7 16 20 20 27 27 27 27 7 6 20 16 Chlorpromazine (ABE3) 3 x 37 Subjects Measure ln Cmax ln AUClast ANOVA-2 (GLM) GMR% CV% 90%CI 115 110 42.3 34.8 99-133 97-124 Chlorpromazine: 90%CIs Measure T v R1 T v R2 ln Cmax 103 - 146 89 - 126 ln AUClast 97 - 128 94 - 125 ANOVA-1 (GLM) R1v R2 72 - 102 85 - 112 Background ACPS Meeting, October 6, 2006 Preliminary results of simulation study were presented Committee was in favor of using a point estimate constraint with scaled average BE Most members favored a minimum sample size of 24 ACPS = Advisory Committee for Pharmaceutical Science Research Project Highly Variable Drugs (HVD) working group evaluated different scaling approaches and study designs. Outcome: – Scaled average bioequivalence, based on within subject variability of reference* * Source: Sam H. Haidar: AAPS/FDA Workshop 5/22/2077, Rockville, MD Objective Determine the impact of scaled average bioequivalence on the power (percent of studies passing) at different levels of within subject variability (CV%), and under different conditions. Methods Study design: • 3-way crossover, e.g., R T R • Sample sizes tested: 24 and 36 • Within subject variability: 15% - 60% CV • Geometric mean ratio: 1 – 1.7 Methods Variables tested: • Impact of increasing within subject variability • Use of point estimate constraint (80125%) • σw0: 0.2 vs. 0.25 vs. 0.294 • Sample size: 24 vs. 36 Methods Statistical Analysis: • Modified Hyslop model* • Number of simulations: 1 million (106)/test • Percent of studies passing was determined using average bioequivalence (80-125% limits), and scaled average bioequivalence (limits determined as a function of reference within subject variability) • Test performed under different conditions *Hyslop et al. Statist. Med. 2000; 19:2885-2897. Hyslop’s model was modified by Donald Schuirmann Source: Sam H. Haidar: AAPS/FDA Workshop 5/22/2077, Rockville, MD Impact of Within Subject Variability • 15% CV • 30% CV • 60% CV Average vs. Scaled Average Bioequivalence CV% = 15, Simulations = 106, N = 36, w0=0.25 Percent of Studies Passing 100 Scaled ABE + Point Estimate Average BE 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio Source: Sam H. Haidar: AAPS/FDA Workshop 5/22/2077, Rockville, MD 1.5 1.6 1.7 Average vs. Scaled Average Bioequivalence CV% = 30, Simulations = 106, N = 36, w0=0.25 Percent of Studies Passing 100 Scaled ABE + Point Estimate Average BE 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio Source: Sam H. Haidar: AAPS/FDA Workshop 5/22/2077, Rockville, MD 1.5 1.6 1.7 Average vs. Scaled Average Bioequivalence CV% = 60, Simulations = 106, N = 36, w0=0.25 Percent of Studies Passing 100 Scaled ABE + Point Estimate Average BE 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio Source: Sam H. Haidar: AAPS/FDA Workshop 5/22/2077, Rockville, MD 1.5 1.6 1.7 Impact of Point Estimate Constraint • Lower variability (30% CV) • Higher variability (60% CV) Average vs. Scaled Average Bioequivalence CV% = 30, Simulations = 106, N = 36, w0=0.25 Percent of Studies Passing 100 Scaled ABE Point Estimate Scaled ABE + Point Estimate Average BE 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio Source: Sam H. Haidar: AAPS/FDA Workshop 5/22/2077, Rockville, MD 1.5 1.6 1.7 Average vs. Scaled Average Bioequivalence CV% = 60, Simulations = 106, N = 36, w0=0.25 Percent of Studies Passing 100 Scaled ABE Point Estimate Scaled ABE + Point Estimate Average BE 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio Source: Sam H. Haidar: AAPS/FDA Workshop 5/22/2077, Rockville, MD 1.5 1.6 1.7 Impact of σW0 σW0 = 0.2 σW0 = 0.25 σW0 = 0.294 Impact of w0 on the Power CV% = 30, Simulations = 106, N = 36 Percent of Studies Passing 100 Average BE Scaled + Point Estimate (w0 = 0.2) Scaled + Point Estimate (w0 = 0.25) Scaled + Point Estimate (w0 = 0.294) 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio 1.5 1.6 1.7 Impact of w0 on the Power CV% = 60, Simulations = 106, N = 36 Percent of Studies Passing 100 Average BE Scaled + Point Estimate (w0 = 0.2) Scaled + Point Estimate (w0 = 0.25) Scaled + Point Estimate (w0 = 0.294) 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio 1.5 1.6 1.7 Average vs. Scaled Average Bioequivalence CV% = 60, Simulations = 106, N = 36 vs. 24, w0=0.25 Percent of Studies Passing 100 Scaled ABE + Point Estimate (N = 24) Average BE (N = 24) Scaled ABE + Point Estimate (N = 36) Average BE (N = 36) 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio 1.5 1.6 1.7 Impact of Different Point Estimate Constraints • Point estimate constraint = ±15% • Point estimate constraint = ± 20% Scaled + Point Estimate constraint of 15% Simulations = 1000000, N = 24 100 CV 30% CV 40% CV 50% CV 60% Percent of Studies Passing 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio Source: Sam H. Haidar: AAPS/FDA Workshop 5/22/2077, Rockville, MD 1.5 1.6 1.7 Scaled + Point Estimate constraint of 20% Simulations = 1000000, N = 24 100 CV 30% CV 40% CV 50% CV 60% Percent of Studies Passing 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio Source: Sam H. Haidar: AAPS/FDA Workshop 5/22/2077, Rockville, MD 1.5 1.6 1.7 Summary Partial replicate, 3-way crossover design appears to work well A point estimate constraint has little impact at lower variability (~30%); more significant effect at greater variability (~60%) A σW0 = 0.25 demonstrates a good balance between a conservative approach, and a practical one Conclusion Scaled ABE presents a reasonable option for evaluating BE of highly variable drugs Practical value, reduction in sample size: Potentially decreasing cost and unnecessary human testing (without increase in patient risk) Use of point estimate constraint addresses concerns that products with large GMR differences may be judged bioequivalent FDA Proposal*: Scaled Average BE for HVA Drugs • Three-period, partial replicate design – Reference product (R) is administered twice – Test product (T) is administered once – Sequences = RTR, TRR, RRT • Sample size: Determined by sponsor (adequate power) – minimum is 24 subjects * Currently under evaluation Source: Sam H. Haidar: AAPS/FDA Workshop 5/22/2077, Rockville, MD FDA Proposal- continued • BE criteria scaled to reference variability (Cmax & AUC) 0.223 BE limits, upper, lower EXP σ wr σ w0 – Where σw0 = 0.25 • The point estimate (test/reference geometric mean ratio) must fall within [0.80-1.25] • Both conditions must be passed by the test product to conclude BE to the reference product Use of reference average BE for HVD • BE criteria scaled to reference variability • 90% upper confidence bound for: Ho: (µT-µR)2 – θ σ2wr must be ≤ 0 Where θ = scaled average BE limit and θ = (ln Δ)2/ σ2wo Where σwo = 0.25 Use a point estimate constraint Both Cmax and AUC must meet criteria Advantages of scaled BE reference scaled • Test product will benefit if: – T variability < R variability • The test product will not benefit if: – T variability > R variability Concerns with Proposed Approach • Firms will conduct a replicate design study and submit results to FDA – If within subject variability ≥ 30%, FDA will use the referencescaled average BE approach – If within subject variability ≤ 30%, FDA will use the unscaled average BE approach • What if the drug is characterized as a borderline HV drug? – FDA simulations showed that study outcome will be the same whether the scaled or unscaled approach is used • Scaling can allow AUC and Cmax GMR to be unacceptably high or low – Acceptance criteria will include a point estimate constraint Concerns with Proposed Approach • What if high variability results from formulations problems or poor study conduct? – If T variability > R variability, no benefit in using scaled approach – The burden is on the applicant to convince FDA that product is a HVD Impact Of Test CV% On Study Power Using Scaled Average BE CVRef% = 30, Simulations = 106, N = 24, w0=0.25 100 CVTest 30% CVTest 40% CVTest 50% CVTest 60% Percent of Studies Passing 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio 1.5 1.6 1.7 Impact Of Small Sample Size On Study Power Using Scaled Average BE CVRef% = 30, CVTest% = 30, Simulations = 10 6, w0=0.25 100 n = 24 n = 21 n = 18 n = 15 n = 12 Percent of Studies Passing 80 60 40 20 0 1.0 1.1 1.2 1.3 1.4 Geometric Mean Ratio 1.5 1.6 1.7 Thank you спасибо